Skip to main content

BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Receives Two Awards in NIH’s AI PREPARE Challenge

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has won two awards in the Pioneering Research for Early Prediction of Alzheimer’s and Related Dementias EUREKA (“PREPARE”) Challenge; the awards were regarding IGC’s entry of the Mexican Health and Aging Study (“MHAS”) database. According to the announcement, the challenge, which is sponsored by the National Institute on Aging, an institute of the National Institutes of Health (“NIH”), is designed to accelerate the development of more accurate, innovative and representative tools for Alzheimer’s and related dementias. IGC’s entry in phase 1 of the PREPARE Challenge won the Disproportionate Impact prize and placed 3rd overall.

“We are honored to win the two PREPARE prizes,” said IGC Pharma CEO Ram Mukunda in the press release. “These recognitions underscore IGC’s leadership in artificial intelligence (‘AI’) and deep-learning research aimed at improving Alzheimer’s disease prediction. We believe our early prediction AI initiatives can offer significant hope to patients and caregivers, create long-time value for shareholders, and alleviate the projected $1 trillion economic burden on the U.S. healthcare system from Alzheimer’s disease.”

To view the full press release, visit https://ibn.fm/ip2aR

About IGC Pharma

IGC Pharma is an artificial intelligence (“AI”)-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer’s disease and transforming patient care with fast-acting, safe and effective solutions. The company’s portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer’s. The IGC-C and IGC-M platforms are advancing in preclinical stages, focusing on metabolic disorders, tau proteins, early plaque formation and multiple disease hallmarks. IGC Pharma’s lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a phase 2 trial for agitation in dementia associated with Alzheimer’s. Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, the company’s AI models are designed to predict potential biomarkers for the early detection of Alzheimer’s, optimize clinical trials and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer’s and related conditions. For more information, visit the company’s website at www.IGCInc.us.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.